Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02065869
Recruitment Status : Active, not recruiting
First Posted : February 19, 2014
Last Update Posted : July 12, 2022
Information provided by (Responsible Party):
Bellicum Pharmaceuticals

Brief Summary:
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially matched family donor. The study will assess whether immune cells, called T cells, from the family donor, that are specially grown in the laboratory and given back to the patient along with the stem cell transplant can help the immune system recover faster after transplant. As a safety measure these T cells have been programmed with a self-destruct switch so that they can be destroyed if they start to react against tissues (Graft versus host disease).

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Leukemia, Acute Myeloid (AML), Child Lymphoma, Non-Hodgkin Myelodysplastic Syndrome Primary Immunodeficiency Anemia, Aplastic Osteopetrosis Hemoglobinopathies Cytopenia Fanconi Anemia Diamond Blackfan Anemia Thalassemia Anemia, Sickle Cell Biological: BPX-501 T cells Drug: rimiducid Phase 2

Detailed Description:

This is a Phase II extension study evaluating the safety and feasibility of BPX-501 T cells infused after partially mismatched, related, TCR alpha beta T cell depleted hematopoietic stem cell transplant (HSCT) in pediatric patients. The purpose of this clinical trial is to determine whether BPX-501 infusion can enhance immune reconstitution in those patients with hematologic disorders, with the potential for reducing the severity and duration severe acute graft versus host disease (GvHD).

The trial will also evaluate the treatment of GvHD by the infusion of dimerizer drug (AP1903/rimiducid) in those subjects who present with GVHD who progress or do not respond to standard of care treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 193 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Extension Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Actual Study Start Date : April 2014
Actual Primary Completion Date : January 30, 2020
Estimated Study Completion Date : February 2033

Arm Intervention/treatment
Experimental: BPX-501 T cells and rimiducid

TCR alpha beta depleted graft infusion with addback of BPX-501 T cells (rivogenlecleucel).

Rimiducid/AP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment

Biological: BPX-501 T cells
1x10E6 cells/kg infused on Day 0
Other Name: rivogenlecleucel

Drug: rimiducid
0.4mg/kg administered IV to treat GVHD
Other Name: AP1903

Primary Outcome Measures :
  1. Event-Free -Survival [ Time Frame: 180 days after transplant ]
    events include TRM (or NRM for malignant patients), severe GVHD (acute Grade 2-4 organ or extensive chronic GVHD) and life threatening infections (Grade 4)

Secondary Outcome Measures :
  1. TRM (non-malignant) or NRM (malignant) [ Time Frame: 180 days after transplant ]
    transplant related mortality or non relapse mortality (patients with malignant disease)

  2. Cumulative incidence and severity of acute (grade 2-4) and chronic GvHD at 180 days [ Time Frame: 180 days after transplant ]
    grades 2-4 acute and chronic GvHD

  3. Time to resolution of acute GvHD after administration of rimiducid [ Time Frame: 180 days after transplant ]
    resolution of acute GvHD

  4. Immune reconstitution [ Time Frame: 180 days after transplant ]
    absolute CD3, CD4 and CD8 count

  5. Disease free/cGvHD [ Time Frame: 180 days after transplant ]
    Disease free/cGvHD survival

  6. Disease status [ Time Frame: 180 days after transplant ]
    Disease status of each specific disease indication

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Month to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age < 18 years and > 1 month (< 1 month upon approval by Sponsor)
  • Life expectancy > 10 weeks
  • Patients deemed clinically eligible for allogeneic stem cell transplantation.
  • Patients may have failed prior allograft
  • Patients with life-threatening acute leukemia (high-risk ALL in 1st CR, ALL in 2nd CR, high-risk AML in 1st CR, AML in 2nd CR.) or myelodysplastic syndromes. Morphological CR must be documented and minimal residual disease measurement before transplantation is recommended.
  • Non-malignant disorders deemed curable by allogeneic transplantation: a. primary immune deficiencies, b. severe aplastic anemia not responding to immune suppressive therapy, c. osteopetrosis d. selected cases of erythroid disorders such as β0 β0 thalassemia major, sickle cell disease, Diamond-Blackfan anemia.

    e. congenital/hereditary cytopenia, including Fanconi Anemia before any clonal malignant evolution (MDS, AML).

Note: Subjects will be eligible if they meet either item 5 OR item 6.

  • Lack of suitable conventional donor (HLA identical sibling or HLA phenotypically identical relative or 10/10 unrelated donor evaluated using high resolution molecular typing) or presence of rapidly progressive disease not permitting time to identify an unrelated donor
  • A minimum genotypic identical match of 5/10 is required.
  • The donor and recipient must be identical, as determined by high resolution typing, on at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA- DRB1 and HLA-DQB1.
  • Lansky/Karnofsky score > 50
  • Signed informed consent by the patient or the patient's parent or guardian for patients who are minors

Exclusion Criteria:

  • Greater than active Grade II acute GvHD or chronic extensive GvHD due to a previous allograft at the time of screening
  • Patient receiving an immunosuppressive treatment for GvHD treatment due to a previous allograft at the time of screening
  • Dysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal value), or of renal function (creatinine clearance <30ml/min/1.73m2)
  • Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)
  • Current clinically active infectious disease (including positive HIV serology or viral RNA)
  • Serious concurrent uncontrolled medical disorder
  • Pregnant or breast feeding female patient
  • Lack of parents'/guardian's informed consent for children who are minors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02065869

Layout table for location information
IRCCS Ospedale Pediatrico Bambino Gesù
Roma, Italy, 00161
United Kingdom
Royal Free London NHS Foundation Trust
London, United Kingdom, NW3 2QG
Institute of Child Health & Great Ormond Street Hospital
London, United Kingdom, WC1N 1EH
Great North Children's Hospital
Newcastle Upon Tyne, United Kingdom, NE1 4LP
Sponsors and Collaborators
Bellicum Pharmaceuticals
Layout table for investigator information
Study Director: Bellicum Pharmaceuticals Bellicum Pharmaceuticals, Inc.
Layout table for additonal information
Responsible Party: Bellicum Pharmaceuticals Identifier: NCT02065869    
Other Study ID Numbers: BP-004
First Posted: February 19, 2014    Key Record Dates
Last Update Posted: July 12, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bellicum Pharmaceuticals:
hematologic neoplasms
hematologic malignancies
primary immune deficiences
congenital cytopenia
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Non-Hodgkin
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Fanconi Anemia
Anemia, Sickle Cell
Anemia, Diamond-Blackfan
Anemia, Aplastic
Primary Immunodeficiency Diseases
Neoplasms by Histologic Type
Hematologic Diseases
Bone Marrow Diseases
Leukemia, Lymphoid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Immunologic Deficiency Syndromes
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Genetic Diseases, Inborn
Anemia, Hypoplastic, Congenital
Congenital Bone Marrow Failure Syndromes